Search clinical trials for: Rasburicase

Total 35 results

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Rasburicase Treatment in Chronic Gouty Arthritis

Chronic Gout

China
The Affiliated Hospital of Qingdao University

Recruiting

Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers

Hyperuricemia

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Recruiting

A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers

Gout

China
M.D. Anderson Cancer Center

Active, not recruiting

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Tumor Lysis Syndrome

United States
St. Jude Children's Research Hospital

Active, not recruiting

Mature B-Cell Lymphoma And Leukemia Study III

Mature B-Cell Lymphoma

United States, Singapore, Egypt
Allena Pharmaceuticals

Terminated

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Chronic Kidney Diseases | Hyperuricemia | Gout

United States
Allena Pharmaceuticals

Completed

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

Chronic Kidney Diseases | Hyperuricemia | Gout

United States
Goethe University

Completed

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Adult Acute Lymphocytic Leukemia | High-grade Lymphoma

Germany
Allena Pharmaceuticals
BDD Pharma Ltd

Completed

Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets

Hyperuricemia | Gout

United Kingdom
Sanofi

Completed

Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia (RAISE)

Lymphoma

China
Allena Pharmaceuticals

Completed

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers (SAD)

Hyperuricemia

United States
Allena Pharmaceuticals

Completed

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) (MAD)

Hyperuricemia | Gout

United States
Erasme University Hospital
Fonds National de la Recherche Scientifique; Fonds Erasme

Completed

Uric Acid Effects on Endothelium and Oxydative Stress

Hypertension | Oxidative Stress | Cardiovascular System | Endothelial Function

Belgium
M.D. Anderson Cancer Center
Sanofi

Completed

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Lymphoma | Leukemia

United States
Washington University School of Medicine

Completed

Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status (UA)

Obesity | Metabolic Syndrome | Hyperuricemia

United States
National Institute on Aging (NIA)

Completed

The Relationship Between Uric Acid and Inflammatory Markers

Healthy Volunteers

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Massachusetts General Hospital

Completed

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
St. Jude Children's Research Hospital
Sanofi

Completed

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Lymphoma | Leukemia | Hyperuricemia | Tumor Lysis Syndrome

United States
Virchow Group

Completed

Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

Hyperuricemia

India
John Sundy
Savient Pharmaceuticals

Completed

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

Gout

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Childhood Diffuse Large Cell Lymphoma | Childhood Immunoblastic Large Cell Lymphoma | Childhood Burkitt Lymphoma | Untreated Childhood Acute Lymphoblastic Leukemia | Stage I Childhood Large Cell Lymphoma | Stage I Childhood Small Noncleaved Cell Lymphoma | Stage II Childhood Large Cell Lymphoma | Stage II Childhood Small Noncleaved Cell Lymphoma and other conditions

United States
Sanofi

Terminated

Rasburicase (Fasturtec) Registration Trial

Hyperuricemia

China
M.D. Anderson Cancer Center
Sanofi

Completed

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Tumor Lysis Syndrome

United States
Sanofi

Terminated

Elitek (Rasburicase) Immuno-Monitoring Study

Tumor Lysis Syndrome

United States
University of Florida

Completed

Lowering Serum Uric Acid to Prevent Acute Kidney Injury (RasbAKI)

Hyperuricemia

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Lymphoma | Leukemia | Tumor Lysis Syndrome

United States
Sanofi

Terminated

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma (GRAAL2)

Hyperuricemia

Germany, Belgium, Italy, France
Sanofi

Completed

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Cancer | Hyperuricemia | Tumor Lysis Syndrome

United States
Sanofi

Completed

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Lymphoma | Leukemia | Hyperuricemia

Japan
Sanofi

Completed

Rasburicase in Tumor Lysis Syndrome

Hyperuricemia

Brazil
Sanofi

Completed

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Hyperuricemia | Tumor Lysis Syndrome | Tumors

United States
Sanofi

Completed

Rasburicase for Hyperuricemia

Nutritional and Metabolic Diseases

Japan
Sanofi

Completed

Fasturtec TLS Treatment / Prophylysis

Tumor Lysis Syndrome

United States
Sanofi

Completed

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Hyperuricemia

Korea, Republic of

Search clinical trials for: Rasburicase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations